Mediating BRAF-mutant melanoma resistance
Drug Target Review
FEBRUARY 26, 2024
Rather than solely identifying tumour-associated mutations which can be specifically targeted for effective treatment, we now need to consider how non-mutational events play into both the development of the primary tumour and the development of therapy resistance.
Let's personalize your content